ITMR - Itamar Medical Ltd.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
14.49
+0.49 (+3.50%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Commodity Channel Index

Commodity Channel Index

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close14.00
Open14.64
Bid14.26 x 800
Ask14.48 x 800
Day's Range14.00 - 14.64
52 Week Range7.66 - 18.03
Volume3,784
Avg. Volume53,922
Market Cap211.405M
Beta (5Y Monthly)0.42
PE Ratio (TTM)N/A
EPS (TTM)-0.48
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est20.13
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • GlobeNewswire

      Itamar™ Medical and BetterNight to Join Forces Offering Referred Patients Home Based Virtual-Care Sleep Solution for the Diagnosis and Treatment of Sleep Apnea

      Itamar Medical Ltd. (ITMR) (ITMR), a medical technology company focused on the development and commercialization of non-invasive medical devices, solutions and a digital health platform to aid in the diagnosis of respiratory sleep disorders, today announced that it has entered into an agreement with Sleep Data Diagnostics and its virtual-care platform BetterNight and Sleep Data Holdings, a leading provider of home-based positive airway pressure (PAP) services. This agreement is designed to radically simplify the process by which both sleep and non-sleep referring physicians, such as cardiologists, can refer their patients for sleep apnea testing with WatchPAT™ through Itamar Medical and BetterNight’s platforms providing a full care pathway that includes testing, medical consultation, continuous positive airway pressure (CPAP) therapy, billing and reimbursement channels.

    • GlobeNewswire

      Itamar™ Medical Implements Broad Range of Actions in Response to COVID-19 Pandemic

      Itamar Medical Ltd. (Nasdaq:  ITMR) (ITMR), a medical technology company focused on the development and commercialization of non-invasive medical devices to aid in the diagnosis of respiratory sleep disorders, today released the following letter from its President and CEO, Gilad Glick. Itamar Medical shares its heartfelt empathy with the communities impacted worldwide by the Coronavirus (COVID-19). Prior to the outbreak of COVID-19, as part of Itamar Medical’s regular business continuity plan, our inventory included a material safety stock, which has allowed us to meet all commitments to date despite early supply chain disruptions in China.

    • GlobeNewswire

      Itamar™ Medical Reports Record Fourth Quarter and Full Year 2019 Revenues

      - Record Fourth Quarter 2019 Revenues Increase 48% to $9.8 Million -  - Reaffirms Full Year 2020 Revenue Guidance of between $39.5 Million and $42.0 Million - - Company to.

    • GlobeNewswire

      Itamar™ Medical and Clalit Research Institute Establish Research Collaboration to Explore WatchPAT Signals’ Ability to Predict Health Outcomes Using Existing Big Data and Artificial Intelligence

      Itamar Medical Ltd. (Nasdaq:  ITMR) (ITMR), a medical technology company focused on the development and commercialization of non-invasive medical devices to aid in the diagnosis of respiratory sleep disorders, today announced that it has entered into a research collaboration agreement with Clalit Research Institute (CRI), a subsidiary of Clalit Health Services (CHS), Israel’s largest state-mandated health service organization. Under the agreement, Itamar and CRI will collaborate to conduct a study designed to determine if data from the WatchPAT signal can help predict cardiovascular health outcomes. The study will use artificial intelligence tools to compare predictive models for different outcomes, such as cardiovascular disease, atrial fibrillation, congestive heart failure and other outcomes.

    • GlobeNewswire

      Itamar™ Medical to Report Fourth Quarter and Full Year 2019 Financial Results and Host Conference Call on Tuesday, March 3, 2020

      Itamar Medical Ltd. (ITMR) (ITMR), a medical technology company focused on the development and commercialization of non-invasive medical devices to aid in the diagnosis of respiratory sleep disorders, announced today that it will report its unaudited financial results for the fourth quarter and full year 2019 before the U.S. market opens on Tuesday, March 3, 2020. The Company will host a conference call that day at 8:00 a.m. Eastern Time, 3:00 p.m. Israel Time to review financial results and provide a corporate update. The call will be hosted by Gilad Glick, President and CEO, and Shy Basson, CFO & US COO.

    • GlobeNewswire

      Itamar™ Medical Announces Publication of COMPASS Study Validating First Scoring Guidelines for WatchPAT™ Device in Diagnosing Sleep Apnea

      Itamar Medical Ltd. (ITMR) (ITMR), a medical technology company focused on the development and commercialization of non-invasive medical devices to aid in the diagnosis of respiratory sleep disorders, today announced publication of results of the COMPASS study validating scoring guidelines that better enable physicians and respiratory technologists to review, verify and interpret WatchPAT automated scoring. The study also found that the use of those guidelines is reliable and improves agreement between WatchPAT and gold standard polysomnography (PSG)-derived sleep and breathing indices across age and gender subgroups.

    • GlobeNewswire

      Itamar™ Medical Announces Closing of Upsized Public Offering of American Depositary Shares and Full Exercise of the Underwriters’ Option to Purchase Additional ADSs

      Itamar Medical Ltd. (ITMR) (ITMR), a medical technology company focused on the development and commercialization of non-invasive medical devices to aid in the diagnosis of respiratory sleep disorders, today announced the closing of its upsized public offering of 2,927,267 American Depositary Shares (“ADSs”), which includes the full exercise of the underwriters’ option to purchase 381,817 additional ADSs, at a public offering price of $13.75 per ADS, for total gross proceeds of approximately $40.25 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Itamar Medical. Each ADS represents 30 ordinary shares of Itamar Medical. All ADSs are being offered by Itamar Medical.

    • GlobeNewswire

      Itamar™ Medical Announces Upsizing and Pricing of Public Offering of American Depositary Shares

      Itamar Medical Ltd. (ITMR) (ITMR), a medical technology company focused on the development and commercialization of non-invasive medical devices to aid in the diagnosis of respiratory sleep disorders, today announced the upsizing and pricing of its public offering of 2,545,450 American Depositary Shares (“ADSs”) at a public offering price of $13.75 per ADS, for total gross proceeds of approximately $35.0 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Itamar Medical. Each ADS represents 30 ordinary shares of Itamar Medical. All of the ADSs are being offered by Itamar Medical.

    • GlobeNewswire

      Itamar™ Medical Announces Proposed $30 Million Offering of American Depositary Shares

      Itamar Medical Ltd. (ITMR) (ITMR), a medical technology company focused on the development and commercialization of non-invasive medical devices to aid in the diagnosis of respiratory sleep disorders, today announced the commencement of a proposed $30 million public offering of American Depositary Shares (“ADSs”). Each ADS represents 30 ordinary shares of Itamar Medical. All of the ADSs to be sold in the offering will be offered by Itamar Medical.

    • GlobeNewswire

      Itamar™ Medical Announces Preliminary Revenue for Fourth Quarter and Full Year 2019 and Revenue Guidance for Full Year 2020

      Itamar Medical Ltd. (ITMR) (ITMR), a company that develops, manufactures and markets non-invasive diagnostic prescription medical devices to aid in the diagnosis of respiratory sleep disorders with a focus on the Core Sleep, Cardiology and Digital Health markets, today reported preliminary unaudited revenue results for the fourth quarter and full year ended December 31, 2019 and announced revenue guidance for the full year 2020. Total revenue for the fourth quarter of 2019 is expected to be $9.6 to $9.8 million, an increase of 46% to 49% compared to $6.6 million in the same quarter in 2018.

    • GlobeNewswire

      Itamar Medical Selected to Participate in the Prestigious Weizmann Institute Project 10K

      Itamar Medical Ltd. (ITMR) (ITMR), a company that develops, manufactures and markets non-invasive diagnostic medical devices for sleep apnea with a focus on the cardiology market, today announced that its WatchPAT has been selected for inclusion in the Weizmann Institute’s Project 10K. One of the largest projects of its kind, the 10K Project is a longitudinal study designed to collect lifestyle and clinical data from 10,000 individuals over ten years and aims to use state-of-the-art artificial intelligence technologies to analyze the data in order to generate personalized predictions for disease risk factors.

    • GlobeNewswire

      Itamar™ Medical and SoClean® Announce Collaboration to Offer WatchPAT™ ONE and other Digital Health Services Through Direct-to-Consumer Channels

      Itamar Medical Ltd. (ITMR) (ITMR), ( “Itamar Medical”) a company that develops, manufactures and markets non-invasive ambulatory diagnostic medical devices for sleep apnea and offers Total Sleep Solution using a cloud based digital health platform, and SoClean Inc., a company that develops, manufactures and markets sleep equipment sanitizers through direct-to-consumer (DTC) channels to the sleep apnea market, today announced a collaboration agreement between their respective wholly owned subsidiaries to make Itamar Medical’s WatchPAT ONE home sleep apnea test and Digital Health Services available to consumers. The collaboration is designed to overcome the barriers to sleep apnea testing and therapy solutions by enabling consumers to purchase remote sleep consultations and home-based sleep test using the WatchPAT ONE in the comfort of their own homes.

    • GlobeNewswire

      Itamar™ Medical Reports Record Third Quarter 2019 Revenues

      - Third Quarter Revenues Increase 33% to $8.1 Million - - WatchPAT™ Revenues Increase 32% in the Third Quarter to $7.6 Million - - Company to Host Conference Call Today at.

    • GlobeNewswire

      Itamar Medical to Present at the Piper Jaffray 31st Annual Healthcare Conference on December 4, 2019

      Itamar Medical Ltd. (ITMR) (ITMR), a company that develops, manufactures and markets non-invasive diagnostic medical devices for sleep apnea and uses a digital healthcare platform to facilitate the continuum of care for effective sleep apnea management with a focus on the cardiology market, announced today that Gilad Glick, President and Chief Executive Officer of Itamar Medical, will participate in a fireside chat at the Piper Jaffray 31st Annual Healthcare Conference in New York, NY, on Wednesday, December 4, 2019 at 4:30 PM ET. A live and archived webcast of the presentation will be available on the investor section of the Company’s website at: www.itamar-medical.com.

    • GlobeNewswire

      Itamar™ Medical to Report Third Quarter 2019 Financial Results and Host Conference Call on Tuesday, November 26, 2019

      Itamar Medical Ltd. (ITMR) (ITMR), a company that develops, manufactures and markets non-invasive diagnostic medical devices for sleep apnea and uses a digital healthcare platform to facilitate the continuum of care for effective sleep apnea management with a focus on the cardiology market, announced today that it will report its unaudited financial results for the third quarter of 2019 before the U.S. market opens on Tuesday, November 26, 2019. The Company will host a conference call that day at 8:00 a.m. Eastern Time, 3:00 p.m. Israel Time to review financial results and provide a corporate update.

    • GlobeNewswire

      Itamar Medical Announces Blue Shield of CA and Blue Cross Blue Shield Federal Employee Plan to Include WatchPAT™ in Their Policies

      Itamar Medical Ltd. (Nasdaq:  ITMR) (ITMR), a company that develops, manufactures, and markets non-invasive diagnostic medical devices for sleep-apnea and uses a digital healthcare platform to facilitate the continuum of care for effective sleep apnea management with a focus on the cardiology market, today announced that Blue Shield of California (BSC) and the Blue Cross Blue Shield Federal Employee Plan (BCBS FEP) have included WatchPAT™ as a covered home sleep apnea diagnostic test. The Company also announced the release of the U.S. Centers for Medicare & Medicaid Services (CMS) 2020 Fee Schedule which is the second year of a 3-year proposed plan by CMS to reevaluate reimbursement in home sleep apnea diagnostic codes.

    • GlobeNewswire

      Itamar Medical Appoints Jennifer Cook, MD, FAHA, FACC, as Global Medical Director

      Itamar Medical Ltd. (ITMR) (ITMR), a company that develops, manufactures and markets non-invasive diagnostic medical devices for sleep apnea and uses a digital healthcare platform to facilitate the continuum of care for effective sleep apnea management with a focus on the cardiology market, announced the appointment of Jennifer Cook, MD, FAHA, FACC to the newly created position of Global Medical Director, effective immediately. In this role, Dr. Cook will lead the Company’s continuing efforts in research, clinical and scientific priorities and oversee scientific collaboration with research institutes, medical associations and key opinion leaders.

    • PR Newswire

      Introducing Investors to Breakthrough Hi-tech and Bio-tech Companies: Frost & Sullivan Publishes Q2 Coverage for Investors to Make Informed Decisions

      NEW YORK , Oct. 7, 2019 /PRNewswire/ -- Equity research is published in the framework of Frost's Independent Equity Research Program. This type of equity research is trusted by investors as it is unbiased ...

    • GlobeNewswire

      Itamar Medical to Present at the Ladenburg Thalmann 2019 Healthcare Conference on September 24, 2019

      Itamar Medical Ltd. (ITMR) (ITMR), a company that develops, manufactures and markets non-invasive diagnostic medical devices for sleep apnea and uses a digital healthcare platform to facilitate the continuum of care for effective sleep apnea management with a focus on the cardiology market, announced today that Gilad Glick, President and Chief Executive Officer of Itamar Medical, will present at the Ladenburg Thalmann 2019 Healthcare Conference in New York, NY, on Tuesday, September 24, 2019 at 12:00 PM ET.

    • GlobeNewswire

      Itamar Medical Reports Record Second Quarter 2019 Revenues

      - Total Second Quarter Revenues Increase 21% to $7.4 Million -  - WatchPATTM Revenues Increase 16% in the Second Quarter to $6.5 Million -  - Company to Host Conference Call.

    • GlobeNewswire

      Itamar Medical to Report Second Quarter 2019 Financial Results and Host Conference Call on Wednesday, August 14, 2019

      Itamar Medical Ltd. (ITMR) (ITMR.TA), a company that develops, manufactures and markets non-invasive diagnostic medical devices for sleep apnea with a focus on the cardiology market, announced today that it will report its unaudited financial results for the second quarter of 2019 before the U.S. market opens on Wednesday, August 14, 2019. The Company will host a conference call that day at 8:00 a.m. Eastern Time, 3:00 p.m. Israel Time to review financial results and provide a corporate update. The call will be hosted by Gilad Glick, President and CEO, and Shy Basson, CFO.

    • PR Newswire

      Frost & Sullivan Begins Coverage of Itamar Medical

      TEL AVIV, Israel , June 26, 2019 /PRNewswire/ -- Itamar Medical's (NASDAQ: ITMR) (TASE: ITMR)  revolutionary technology enables cardiologists to make better decisions and results in 30% assumed revenue ...

    • GlobeNewswire

      Itamar Medical’s WatchPAT™ One, the First and Only Fully Disposable Home Sleep Apnea Test Receives FDA 510(k) Clearance

      Itamar Medical Ltd. (ITMR) (ITMR.TA), a company that develops, manufactures and markets non-invasive diagnostic medical devices for sleep apnea with a focus on the cardiology market, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration for WatchPAT One, the latest innovation of its WatchPAT technology and the first and only fully disposable Home Sleep Apnea Test (HSAT). WatchPAT One incorporates the technology and comfort advances of WatchPAT 300, which received 510(k) clearance in August 2018 and was launched in March 2019.

    • GlobeNewswire

      Itamar Medical and BioTel Heart, a Division of BioTelemetry, Expand Collaboration to Offer Itamar’s Total Sleep Solution™ to BioTel Heart Cardiology Customers

      Itamar Medical Ltd. (NASDAQ and TASE:ITMR), a company that develops, manufacturers and markets non-invasive diagnostic devices for sleep apnea with a focus on the cardiology market, and BioTel Heart, a division of BioTelemetry, Inc. (BEAT), the leading remote medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, today announced an expanded collaboration to make Itamar Medical’s Total Sleep Solution available to select BioTel Heart cardiology customers in the United States. The collaboration is designed to respond to the growing demand for home sleep apnea testing among cardiologists, who recognize effective sleep apnea management as a critical strategy for improving health in patients with cardiac disease.

    • GlobeNewswire

      Itamar Medical Reports First Quarter 2019 Financial Results

      - WatchPAT™ Revenues Increase 15% to $5.8 Million -  - U.S. WatchPAT Revenues Increase 34% to $4.3 Million - - Total Revenues Increase 11% to $6.1 Million - CAESAREA, Israel,.